Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by MMABStraderon Apr 08, 2022 8:13pm
135 Views
Post# 34589705

RE:RE:RE:This line says it all...

RE:RE:RE:This line says it all...
MM, I agree with almost everything you said in your post. But what I think you and others don't understand is that Paradigm's price target of $2.10 means it is the forecasted price/anticipated price/guestimated share price sometime in the next 12 months.  I'm sure they don't think this is the highest price Spectral will ever achieve, or an end game/buy out price. 

I believe Paradigm wiIl have another higher share price projection before 12 months from now assuming the timelines stay in tact.  If/when Spectral gets a U.S. exchange listing I would expect many analysts will have higher and different share price projections.

Personally, I'm very happy with a price projection of $2.10 twelve months from now.  I am a long term investor and have periodically added to my position and have an average U.S. share cost of 30 cents a share. Twelve  months from now someone will probably project a price of $4 to $7 and  I'll be even happier. What Paradigm projected was a transitory price projection not unlike what happens with price projections for Tesla, Intel, Ford, etc. Share price projections always move up and down over time.

Don't over think it!  On balance, I beleive the Paradigm article was a positive for share price and for new investors considering buying Spectral shares.
<< Previous
Bullboard Posts
Next >>